$4.55
4.21% day before yesterday
Nasdaq, Dec 27, 10:06 pm CET
ISIN
US7611234052
Symbol
RSLS

ReShape Lifesciences, Inc. Stock price

$4.55
-1.20 20.87% 1M
-6.93 60.38% 6M
-9.93 68.58% YTD
-10.99 70.72% 1Y
-5,505.45 99.92% 3Y
-16,438.45 99.97% 5Y
-362,501,995.45 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.20 4.21%
ISIN
US7611234052
Symbol
RSLS
Sector

Key metrics

Market capitalization $3.24m
Enterprise Value $2.59m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.32
P/S ratio (TTM) P/S ratio 0.40
P/B ratio (TTM) P/B ratio 2.16
Revenue growth (TTM) Revenue growth -16.55%
Revenue (TTM) Revenue $8.18m
EBIT (operating result TTM) EBIT $-7.92m
Free Cash Flow (TTM) Free Cash Flow $-6.20m
Cash position $840.00k
EPS (TTM) EPS $-16.40
P/E forward negative
P/S forward 0.44
EV/Sales forward 0.32
Short interest 5.39%
Show more

Is ReShape Lifesciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

ReShape Lifesciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast ReShape Lifesciences, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast ReShape Lifesciences, Inc.:

Buy
100%

Financial data from ReShape Lifesciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
8.18 8.18
17% 17%
100%
- Direct Costs 2.60 2.60
42% 42%
32%
5.58 5.58
5% 5%
68%
- Selling and Administrative Expenses 11 11
43% 43%
140%
- Research and Development Expense 2.02 2.02
0% 0%
25%
-7.90 -7.90
53% 53%
-97%
- Depreciation and Amortization 0.03 0.03
95% 95%
0%
EBIT (Operating Income) EBIT -7.92 -7.92
55% 55%
-97%
Net Profit -7.07 -7.07
73% 73%
-86%

In millions USD.

Don't miss a Thing! We will send you all news about ReShape Lifesciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ReShape Lifesciences, Inc. Stock News

Neutral
Seeking Alpha
about one month ago
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO Krishna Gupta - Director, Vyome Therapeutics Conference Call Participants Jason McCarthy - Maxim Group Operator Good afternoon, and thank you for joining the ReShape Lifesciences Thi...
Neutral
GlobeNewsWire
about 2 months ago
Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024 Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024
Neutral
GlobeNewsWire
about 2 months ago
IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Health Canada has updated the Medical Device License granting approval for the company's next generation, enhanced Lap-Band® 2.0 FLEX and Tubing Kit.
More ReShape Lifesciences, Inc. News

Company Profile

ReShape Lifesciences Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. It operates through the following segments: Lap-Band, ReShape Vest and ReShape vBloc. The company was founded on December 2002 and is headquartered in San Clemente, CA.

Head office United States
CEO Paul Hickey
Employees 31
Founded 2002
Website www.reshapelifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today